Premium
Decreased expression of Beclin 1 correlates with a metastatic phenotypic feature and adverse prognosis of gastric carcinomas
Author(s) -
Chen YingBo,
Hou JingHui,
Feng XingYu,
Chen Shi,
Zhou ZhiWei,
Zhang XiaoShi,
Cai MuYan
Publication year - 2011
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.22151
Subject(s) - medicine , immunohistochemistry , cancer , proportional hazards model , stage (stratigraphy) , univariate analysis , survival analysis , autophagy , oncology , pathology , metastasis , apoptosis , cancer research , multivariate analysis , biology , paleontology , biochemistry
Abstract Background and Objectives Beclin 1 plays a critical role in the regulation of autophagy, apoptosis, differentiation and the development and progression of cancer. The clinicopathological significance of Beclin 1 expression in patients with gastric carcinoma (GC) has not been yet elucidated. Methods Immunohistochemistry (IHC) was performed to investigate the Beclin 1 expression in GCs and normal mucosal tissues. Receiver operating characteristic curve analysis, spearman's rank correlation, Kaplan–Meier plots and Cox proportional hazards regression model were used to analyze the data. Results The highly expressed Beclin 1 was observed in 90/155 (58.1%) of GCs, in 24/60 (40.0%) adjacent mucosal tissues and in 13/30 (43.3%) of normal gastric mucosa tissues ( P = 0.036). Decreased expression of Beclin 1 in cancer cells was significantly correlated with poor differentiation, nodal and distant metastasis, advanced TNM stage, and tumor relapse. More importantly, Decreased expression of Beclin 1 was associated with shorter survival as evidenced by univariate and multivariate analysis. Conclusions Our findings provide a basis for the concept that decreased expression of Beclin 1 in GC may be important in the acquisition of a metastatic phenotype, suggesting that decreased Beclin 1 expression, as examined by IHC, is an independent biomarker for poor prognosis of patients with GC. J. Surg. Oncol. 2012; 105:542–547. © 2011 Wiley Periodicals, Inc.